Peter MacCallum Cancer Centre

AdvanCell Announces First Patient Dosed in Phase I/II TheraPb Clinical Trial of 212Pb-ADVC001 in Metastatic Prostate Cancer

Retrieved on: 
Tuesday, November 7, 2023

“The first patient dosed with an AdvanCell therapeutic candidate represents a major milestone for the Company, our scientists, clinical trial sites, and our patients,” said Andrew Adamovich, CEO of AdvanCell.

Key Points: 
  • “The first patient dosed with an AdvanCell therapeutic candidate represents a major milestone for the Company, our scientists, clinical trial sites, and our patients,” said Andrew Adamovich, CEO of AdvanCell.
  • “We believe that 212Pb is the ideal radioisotope to realise the full therapeutic power of Targeted Alpha Therapy.
  • “We are excited to be moving this 212Pb-based therapy forward in the TheraPb clinical study.”
    Developed the world’s first 212Pb-based Targeted Alpha Therapy to enter clinical trials in metastatic prostate cancer.
  • Developed a proprietary target discovery and ligand development program encompassing a robust pipeline of Targeted Alpha Therapies to treat cancer.

STORM Therapeutics publishes data in Cancer Discovery showing induction of anti-tumour immunity by METTL3 inhibition

Retrieved on: 
Tuesday, August 8, 2023

CAMBRIDGE, England, Aug. 8, 2023 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is pleased to announce that it has published a scientific manuscript in the internationally recognised scientific journal Cancer Discovery.

Key Points: 
  • Using pre-clinical cancer models, the study shows that pharmacological inhibition of METTL3 induces double-stranded RNA formation and a profound cell-intrinsic interferon response that potentiates T-cell killing of cancer cells.
  • Oliver Rausch, Chief Scientific Officer of STORM Therapeutics and joint senior author of the study, said, "We are pleased to share this new data with the scientific community.
  • Our study identifies a novel therapeutic mechanism triggered by METTL3 inhibition that opens a significant opportunity for METTL3 inhibitors in immuno-oncology.
  • Andrew A Guirguis, Yaara Ofir-Rosenfeld et al, 2023, Cancer Discovery (advanced online publication) https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.C...

STORM Therapeutics publishes data in Cancer Discovery showing induction of anti-tumour immunity by METTL3 inhibition

Retrieved on: 
Tuesday, August 8, 2023

CAMBRIDGE, England, Aug. 8, 2023 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is pleased to announce that it has published a scientific manuscript in the internationally recognised scientific journal Cancer Discovery.

Key Points: 
  • Using pre-clinical cancer models, the study shows that pharmacological inhibition of METTL3 induces double-stranded RNA formation and a profound cell-intrinsic interferon response that potentiates T-cell killing of cancer cells.
  • Oliver Rausch, Chief Scientific Officer of STORM Therapeutics and joint senior author of the study, said, "We are pleased to share this new data with the scientific community.
  • Our study identifies a novel therapeutic mechanism triggered by METTL3 inhibition that opens a significant opportunity for METTL3 inhibitors in immuno-oncology.
  • Andrew A Guirguis, Yaara Ofir-Rosenfeld et al, 2023, Cancer Discovery (advanced online publication) https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.C...

ImmunOs Therapeutics Announces Initiation of Dosing in Phase 1 Trial of Lead Compound IOS-1002

Retrieved on: 
Wednesday, May 24, 2023

Schlieren (Zurich Area), Switzerland – May 24, 2023 – ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the initiation of dosing of patients in a Phase 1 trial of its lead program IOS-1002 in Australia.

Key Points: 
  • Schlieren (Zurich Area), Switzerland – May 24, 2023 – ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the initiation of dosing of patients in a Phase 1 trial of its lead program IOS-1002 in Australia.
  • IOS-1002 is a first-in-class checkpoint inhibitor targeting LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1 for the treatment of advanced solid tumors.
  • Primary endpoints of the current Phase 1a, first-in-human, open-label, non-randomized, multicenter study will be the safety and tolerability of IOS-1002.
  • "We are excited that our lead compound IOS-1002 has entered into a first-in-human trial and that patients are being dosed," said Sean R. Smith, CEO of ImmunOs Therapeutics.

SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023

Retrieved on: 
Monday, April 17, 2023

The data are being presented today in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place in Orlando, Florida.

Key Points: 
  • The data are being presented today in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place in Orlando, Florida.
  • “The lifirafenib plus mirdametinib combination represents a novel targeted approach to treat solid tumors driven by RAS/RAF mutations, and other MAPK pathway aberrations.
  • As of the data cut-off of January 20, 2023, 71 patients were treated across 9 dose levels evaluating different dosing regimens.
  • Of the 4 endometrial cancer patients treated, 2 (50%) had objective responses in tumors that harbor BRAF fusion mutation or KRAS mutation, respectively.

BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023

Retrieved on: 
Monday, April 17, 2023

The data are being presented today in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place in Orlando, Florida.

Key Points: 
  • The data are being presented today in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place in Orlando, Florida.
  • View the full release here: https://www.businesswire.com/news/home/20230417005339/en/
    “The lifirafenib plus mirdametinib combination represents a novel targeted approach to treat solid tumors driven by RAS/RAF mutations, and other MAPK pathway aberrations.
  • As of the data cut-off of January 20, 2023, 71 patients were treated across 9 dose levels evaluating different dosing regimens.
  • Of 17 patients with LGSOC treated, 10 patients (59%) had objective responses, with median duration of treatment of approximately 26 months.

BIOMODAL LAUNCHES SOLUTION TO SIMULTANEOUSLY SEQUENCE GENETICS AND EPIGENETICS IN ONE WORKFLOW

Retrieved on: 
Thursday, April 13, 2023

CAMBRIDGE, England, April 13, 2023 /PRNewswire/ -- The duet multiomics solution is the world's first single-base-resolution sequencing technology that enables the simultaneous phased reading of genetic and epigenetic information in a single sample, with one workflow, using any sequencer. The hardware-agnostic product provides more epigenetic information from a single low input DNA library without complex, resource intensive bioinformatics or harsh chemical treatment. Recently published in Nature Biotechnology, the solution provides a more complete picture of the information stored in genomes availing new insights from applications throughout biomedicine.

Key Points: 
  • "Our novel solution removes the technical barriers that have previously held back our broader understanding of epigenetics.
  • Now, our customers can accelerate their research with a more comprehensive view of regulatory function across the genome, through the interplay of genetics and epigenetics at read level.
  • The duet multiomics solution empowers applications across numerous fields of disease research, delivering greater biological insights into cancer, neurodegenerative disease, ageing, cell biology and population genetics.
  • Using cell-free DNA via liquid biopsy, duet multiomics can simultaneously detect powerful genetic and methylation biomarkers in an individual's blood to provide unique disease insights.

BIOMODAL LAUNCHES SOLUTION TO SIMULTANEOUSLY SEQUENCE GENETICS AND EPIGENETICS IN ONE WORKFLOW

Retrieved on: 
Thursday, April 13, 2023

CAMBRIDGE, England, April 13, 2023 /PRNewswire/ -- The duet multiomics solution is the world's first single-base-resolution sequencing technology that enables the simultaneous phased reading of genetic and epigenetic information in a single sample, with one workflow, using any sequencer. The hardware-agnostic product provides more epigenetic information from a single low input DNA library without complex, resource intensive bioinformatics or harsh chemical treatment. Recently published in Nature Biotechnology, the solution provides a more complete picture of the information stored in genomes availing new insights from applications throughout biomedicine.

Key Points: 
  • "Our novel solution removes the technical barriers that have previously held back our broader understanding of epigenetics.
  • Now, our customers can accelerate their research with a more comprehensive view of regulatory function across the genome, through the interplay of genetics and epigenetics at read level.
  • The duet multiomics solution empowers applications across numerous fields of disease research, delivering greater biological insights into cancer, neurodegenerative disease, ageing, cell biology and population genetics.
  • Using cell-free DNA via liquid biopsy, duet multiomics can simultaneously detect powerful genetic and methylation biomarkers in an individual's blood to provide unique disease insights.

Circulating Tumor DNA Guides Chemotherapy Use in Stage II Colon Cancer

Retrieved on: 
Saturday, June 4, 2022

The real-world study is thought to be the first to use ctDNA to guide follow-up chemotherapy decisions in stage II colon cancer patients after surgery to determine if certain patients can be spared from this form of treatment based.

Key Points: 
  • The real-world study is thought to be the first to use ctDNA to guide follow-up chemotherapy decisions in stage II colon cancer patients after surgery to determine if certain patients can be spared from this form of treatment based.
  • Standard care follows traditional guidelines based on clinicopathological features that are associated with higher cancer risk.
  • If tumor DNA was not found, then those patients in the ctDNA-guided group were not treated with chemotherapy.
  • In previous studies, scientists found an 80% risk of recurrence in stage II colon cancer patients with detectable ctDNA who did not receive chemotherapy.

Adela Announces Executive and Board of Directors Appointments and Formation of Scientific Advisory Board

Retrieved on: 
Monday, May 23, 2022

TORONTO, May 23, 2022 /PRNewswire/ -- Adela, Inc., focused on the detection of cancer and other high-morbidity, high-mortality conditions through a blood test, has made appointments to the Executive Team and Board of Directors that add to the deep industry and scientific expertise of the current team. The company has also formed a Scientific Advisory Board comprised of renowned scientists and clinicians.

Key Points: 
  • The company has also formed a Scientific Advisory Board comprised of renowned scientists and clinicians.
  • "I am thrilled to welcome Chris Parker, Chief Business Officer to Adela's Executive Team," said Scott Bratman, Chief Executive Officer at Adela.
  • Chris Parker joins Adela from Exact Sciences, where he served as Vice President, Business Development and was responsible for inorganic growth strategy.
  • Adela has also formed a Scientific Advisory Board (SAB) with deep expertise in cancer biology, machine learning, and cancer screening.